A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...

For adults, about half think it’s a good thing, and about 2 in 10 think it’s a bad thing. The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

These weight loss medications, administered via injections, work by mimicking a hormone called GLP-1, which helps regulate appetite and blood sugar levels.

While Hannah hasn't found the drug to be useful for weight loss, six months on, she's more than willing to keep paying the ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

By Dr. Arshpreet Saraan Weight loss injectables have been making headlines in the papers and across social media the past couple of years, but how much do we really know about them?   Ozempic, Wegovy, ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...